Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.
Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript
Investors need to pay close attention to EW stock based on the movements in the options market lately.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Bernard J. Zovighian CEO | NYSE Exchange | 28176E108 CUSIP |
| US Country | 15,800 Employees | - Last Dividend | 1 Jun 2020 Last Split | 27 Mar 2000 IPO Date |
Edwards Lifesciences Corporation specializes in providing advanced medical technologies tailored to diagnose and treat structural heart diseases and conditions requiring critical care monitoring. The company has a global footprint, offering its state-of-the-art products and solutions across the United States, Europe, Japan, and other international markets. Founded in 1958, Edwards Lifesciences has its headquarters in Irvine, California, and leverages both a direct sales force and a network of independent distributors to reach its market.
Under the Edwards SAPIEN family, these products offer minimally invasive options for replacing aortic heart valves, enabling significant improvements in patient outcomes and recovery times.
Targeting mitral and tricuspid valve diseases, products under the PASCAL PRECISION and Cardioband names offer advanced solutions for valve repair and replacement, supporting heart function restoration.
Edwards provides various surgical solutions including the INSPIRIS aortic surgical valve and the INSPIRIS RESILLA valve, featuring RESILIA tissue and VFit technology for enhanced durability. The KONECT RESILIA and MITRIS RESILIA valve products support complex procedures with pre-assembled tissue valves and innovative designs for better patient outcomes.
The company's critical care portfolio includes hemodynamic monitoring systems such as FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight, designed to measure heart function and fluid status in surgical and ICU settings accurately. The HemoSphere monitoring platform visually displays critical physiological information, and the Acumen Hypotension Prediction Index software utilizes advanced algorithms to predict and alert clinicians of potential dangerous drops in blood pressure.